You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic PD-(L)1-naïve melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Chapel Hill, Raleigh (FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab)

Active, not recruiting
Has Results
  • Melanoma
  • FDG PET/CT scan
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Jan 10, 2023

Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma Trial run by the National Cancer Institute

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Monitoring T Cell Responses in Melanoma, Lung and Other Cancer

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +9 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Oct 4, 2023

Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Immune checkpoint inhibitor
  • Ljubljana, Slovenia
    Institute of Oncology Ljubljana
May 17, 2023

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

Generation ofArtificial Intelligence Algorithm Based on Analysis

Not yet recruiting
  • Metastatic Melanoma
  • Photo
  • (no location specified)
May 3, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Boston, Massachusetts
  • +2 more
Sep 17, 2022

Metastatic Melanoma Trial in Herlev (Nivolumab, PD-L1/IDO peptide vaccine)

Recruiting
  • Metastatic Melanoma
  • Herlev, Denmark
  • +1 more
Mar 15, 2022

NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
Oct 26, 2022

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in

Not yet recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 28, 2023

Tumor Metastasis Trial in Canada, United Kingdom, United States (BI 754091, BI 754111, BI 836880)

Active, not recruiting
  • Neoplasm Metastasis
  • BI 754091
  • +2 more
  • La Jolla, California
  • +16 more
Jan 9, 2023

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab

Recruiting
  • Unresectable Melanoma
  • +3 more
  • Sargramostim (GM-CSF)
  • Pembrolizumab (anti-PD-1)
  • Boston, Massachusetts
  • +1 more
Jul 6, 2022

Melanoma Trial (ONCOS-102, Balstilimab)

Not yet recruiting
  • Melanoma
  • ONCOS-102
  • Balstilimab
  • (no location specified)
Oct 24, 2022

Melanoma, Renal Cell Carcinoma, Brain Metastases Trial in New Haven (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma
  • +6 more
  • New Haven, Connecticut
    Yale University
Feb 18, 2022

Metastatic Melanoma Trial in Germany (molecular tissue analysis)

Recruiting
  • Metastatic Melanoma
  • molecular tissue analysis
  • Tuebingen, Baden-Württemberg, Germany
  • +13 more
Feb 28, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Local Progression or Metastatic Melanoma With Failed First-line Treatment Trial in Beijing (Pexa-Vec combined with ZKAB001,

Recruiting
  • Local Progression or Metastatic Melanoma With Failed First-line Treatment
  • Pexa-Vec combined with ZKAB001
  • ZKAB001 monotherapy
  • Beijing, China
    Beijing Cancer Hospital
Mar 30, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +20 more
  • Neoantigen Peptide Vaccine
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 7, 2022

Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Anti-PD-L1 Monoclonal Antibody IMC-001
  • Punch Biopsy
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • 89Zr-atezolizumab PET/CT
  • (no location specified)
Feb 22, 2023

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting Trial in Lausanne (Pembrolizumab, Pembrolizumab - additional

Active, not recruiting
  • Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting
  • Lausanne, Switzerland
    Olivier Michielin
Jan 17, 2022